Reuters logo
BRIEF-Enanta Pharmaceuticals reports positive phase 1 A/B clinical results for its lead fxr agonist
October 23, 2017 / 11:38 AM / 2 months ago

BRIEF-Enanta Pharmaceuticals reports positive phase 1 A/B clinical results for its lead fxr agonist

Oct 23 (Reuters) - Enanta Pharmaceuticals Inc:

* Enanta Pharmaceuticals announces positive phase 1 a/b clinical results for its lead fxr agonist, edp-305

* Enanta Pharmaceuticals Inc - ‍edp-305 was generally safe and well tolerated over a broad range of single and multiple doses​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below